Skip to content Skip to footer
Menu Close
Close
Psychiatry

Join Major Depressive Disorder Clinical Trials Focused on Personalized Psychiatry and Modern Treatment Strategies

MDD Clinical Research

Major Depressive Disorder Clinical Trials in Houston, TX

Major Depressive Disorder (MDD) is a mental health condition that can affect mood, energy, sleep, and overall daily functioning. It may range from moderate to severe and, in some cases, symptoms can persist despite standard treatment options.

Zillan Clinical Research is conducting the EXTEND trial, a Phase III long-term extended study that is enrolling patients who have already completed either the APPROACH or EMBRACE clinical trials and received both dose administrations of study medication in those trials.

Check Eligibility
About This Study

Exploring New Possibilities in Major Depressive Disorder Care

When depression doesnu2019t improve with standard treatment, it can continue to affect how a person feels, thinks, and functions each day. This is especially common in moderate to severe major depressive disorder (MDD) with inadequate response to antidepressants.

The current clinical depression research studies at Zillan Clinical Research are evaluating the safety and long-term efficacy of an investigational deuterated psilocin analog when used alongside ongoing antidepressant therapy and structured psychological support. Eligible participants continue on their current antidepressant therapy and receive structured psychological support and close safety monitoring throughout the study, at no cost.

Now Enrolling

Current Status

Major Depressive Disorder (MDD)

Condition
Partner With Us
Our Values

Why Patients Trust Us

At Zillan Clinical Research, we conduct ethical, high-quality clinical studies focused on patient safety, scientific integrity, and advancing innovative treatments for better health outcomes.

Integrity

Conducting all studies with honesty, transparency, and strict ethical standards

Patient Safety

Prioritizing participant well-being through close monitoring and care

Scientific Excellence

Following high-quality research practices and global clinical standards

Innovation

Supporting advanced research approaches that drive medical progress

Diversity & Inclusion

Ensuring studies reflect real-world patient populations

Trusted Oversight

Operating under regulated, GCP-compliant clinical research processes

FAQ

Frequently Asked Questions

It is a Phase III long-term extension study evaluating the safety and long-term efficacy of CYB003, an investigational deuterated psilocin analog, in adults with Major Depressive Disorder who completed the earlier APPROACH or EMBRACE trials.

Eligibility is limited to adults (ages 18u201385) who have already successfully completed either the APPROACH (CYB003-002) or EMBRACE (CYB003-003) trials and received both dose administrations of study medication. Participants must also have maintained their antidepressant medication at a stable dose throughout the prior trial.
Participants receive structured study visits, mental health evaluations, safety monitoring, and access to investigational treatment alongside standard care.
A major depressive disorder study aims to assess how investigational therapies may improve symptoms, tolerability, and overall treatment outcomes.
Yes, several research sites conduct studies evaluating new treatment approaches for individuals living with moderate to severe MDD.
All studies follow strict clinical guidelines with close monitoring by qualified professionals to ensure participant safety throughout the process.
Still have questions? Our team is here to support you with your clinical research needs.
Contact Our Team

Join Us

Supporting Innovation
Through Clinical Trials

Join studies designed to advance medical knowledge and support the development of next-generation therapies.
Take the First Step Today